The Cowen and Company36th Annual Health Care Conference on Wednesday, March 9, 2016, at 10:00 a.m. ETat the Boston Marriott Copley Placein Boston.
The 28th Annual
ROTH Conferenceon Monday, March 14, 2016, at 2:30 p.m. PTat the Ritz-Carlton, Laguna Niguelin Orange County, CA.
The Alliance for Regenerative Medicine’s 4th Annual Cell &
Gene Investor Day on
Tuesday, March 22, 2016, at 1:55 p.m. ETat the Metropolitan Clubin New York City.
To access the live webcasts of bluebird bio’s presentations, please visit the “Calendar of Events” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the conferences.
About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy expertise
and gene editing capabilities, bluebird bio has built an integrated
product platform with broad potential application to severe genetic
diseases and cancer. bluebird bio’s gene therapy clinical programs
include its Lenti-D™ product candidate, currently in a Phase 2/3 study,
called the Starbeam Study, for the treatment of cerebral
adrenoleukodystrophy, and its LentiGlobin® BB305 product candidate,
currently in three clinical studies for the treatment of
transfusion-dependent ß-thalassemia, also known as ß-thalassemia major,
and severe sickle cell disease. bluebird bio’s oncology pipeline is
built upon the company’s leadership in lentiviral gene delivery and T
cell engineering, with a focus on developing novel T cell-based
immunotherapies, including chimeric antigen receptor (CAR T) and T cell
receptor (TCR) therapies. bluebird bio’s lead oncology program, bb2121,
is an anti-BCMA CAR T program partnered with
bluebird bio has operations in
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding bluebird bio’s existing product candidates and
research programs. Any forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to, risks that the preliminary results from our
clinical trials will not continue or be repeated in our ongoing clinical
trials, the risk that previously conducted studies involving similar
product candidates will not be repeated or observed in ongoing or future
studies involving current product candidates, the risk of cessation or
delay of any of the ongoing or planned clinical studies and/or our
development of our product candidates, the risk of a delay in the
enrollment of patients in our clinical studies, the risk that our
Source: bluebird bio, Inc.
bluebird bio, Inc.
Manisha Pai, 617-245-2107
Pure Communications, Inc.
Dan Budwick, 973-271-6085